Oral Therapy for Infective Endocarditis: Where Do We Stand?
Pathogens · 06.12.2025 · 14 (12) · 1249
DOI: 10.3390/pathogens14121249 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 06.12.2025. Verfasst von Fatima Allaw und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The View Hospital, Al Qutaifiya, Qatar. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Endocarditis, Endocarditis, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Standard therapy for infective endocarditis (IE) usually requires 4–6 weeks of intravenous (IV) antibiotics, ensuring sustained bactericidal concentrations, yet resulting in prolonged hospitalization and increased cost of care. These challenges have driven interest in oral antibiotic therapy (OAT) as a step-down strategy for selected, clinically stable patients. This review summarizes the clinical evidence and pharmacokinetic and pharmacodynamic (PK/PD) rationale and practical considerations supporting step-down OAT in IE. Antibiotics such as amoxicillin, fluoroquinolones, linezolid, and rifampicin have high bioavailability and maintain effective serum and tissue concentrations, and can be used as a safe transition from IV to oral therapy. The pivotal POET randomized controlled trial (RCT) demonstrated noninferiority of OAT compared with continued IV therapy in stable patients with left-sided IE caused by Streptococcus spp., Enterococcus faecalis, methicillin-susceptible Staphylococcus aureus, or coagulase-negative staphylococci. Further real-world studies and meta-analyses confirmed comparable efficacy and safety, with reduced catheter-related complications and shorter hospitalization length for patients receiving OAT. The latest European Society of Cardiology (ESC) guidelines have incorporated OAT regimens derived from the POET protocol for stable patients meeting specific criteria, while the American Heart Association guidelines have not yet been revised. Many areas remain uncertain, such as the optimal timing of transition to oral therapy; the ideal antibiotic combinations and dosing; and the applicability to complex cases such as methicillin-resistant S. aureus (MRSA), Gram-negative, or pediatric infections. Overall, clinical evidence supports OAT as a safe and effective alternative to prolonged IV therapy in selected patients with IE, highlighting a major step toward more individualized, patient-centered management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, The View Hospital, Al Qutaifiya, Qatar.
- College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar.
- Division of Infectious Diseases, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA.
- Division of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine American, University of Beirut, Beirut 1107 2020, Lebanon.
- Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
ORCID-Profile: Maya Dagher, Souha S Kanj
Zitieren
APA
Allaw, F., Dagher, M., Saliba, H., Khalil, J., & Kanj, S. S. (2025). Oral Therapy for Infective Endocarditis: Where Do We Stand?. Pathogens, 14(12), 1249. https://doi.org/10.3390/pathogens14121249
Vancouver
Allaw F, Dagher M, Saliba H, Khalil J, Kanj SS. Oral Therapy for Infective Endocarditis: Where Do We Stand?. Pathogens. 2025;14(12):1249. doi:10.3390/pathogens14121249
BibTeX
@article{Allaw2025,
author = {Allaw, Fatima and Dagher, Maya and Saliba, Hiba and Khalil, Jana and Kanj, Souha S},
title = {Oral Therapy for Infective Endocarditis: Where Do We Stand?},
journal = {Pathogens},
year = {2025},
volume = {14},
number = {12},
pages = {1249},
doi = {10.3390/pathogens14121249}
}
EUVIMED